Get started
Author

Perttu Koskenvesa

Observed names: Koskenvesa P, Koskenvesa, Perttu, P Koskenvesa
ORCID: 0000-0002-7121-321X
Observed ORCID: 0000-0002-7121-321X
OpenAlex ID: A5033314197
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
2018 · Susanne Saussele, Johan Richter, et al. · The Lancet Oncology · 619
PDF
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia
2008 · Kimmo Porkka, Perttu Koskenvesa, et al. · Blood · 443
PDF
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
2015 · V S Hoffmann, M Baccarani, et al. · Leukemia · 256
PDF
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
2016 · M Ilander, U Olsson-Strömberg, et al. · Leukemia · 251
PDF
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
2011 · Bengt Simonsson, Tobias Gedde-Dahl, et al. · Blood · 194
PDF
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
2016 · V S Hoffmann, M Baccarani, et al. · Leukemia · 105
PDF
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML
2018 · Oscar Brück, Sami Blom, et al. · Leukemia · 103
PDF
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
2020 · Markus Pfirrmann, Richard E. Clark, et al. · Leukemia · 96
PDF
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
2024 · Francois-Xavier Mahon, Markus Pfirrmann, et al. · Journal of Clinical Oncology · 71
PDF
Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
2016 · H Hjorth-Hansen, J Stentoft, et al. · Leukemia · 71
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia
2020 · Shady Adnan Awad, Matti Kankainen, et al. · Blood Advances · 67
PDF
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients
2013 · S Mustjoki, J Richter, et al. · Leukemia · 65
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study ( N ord CML 006)
2014 · Henrik Hjorth‐Hansen, Leif Stenke, et al. · European Journal Of Haematology · 63
PDF
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
2020 · Shady Adnan Awad, Olli Dufva, et al. · Leukemia · 61
PDF
Chronic myeloid leukemia patients’ adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians
2014 · Meri Kekale, Marja Airaksinen, et al. · Patient Preference and Adherence · 50
PDF
Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study
2016 · Meri Kekäle, Tim Söderlund, et al. · Journal of Advanced Nursing · 32
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis
2017 · Francis J. Giles, Delphine Rea, et al. · Journal of Cancer Research and Clinical Oncology · 29
PDF
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
2022 · Shady Adnan Awad, Oscar Brück, et al. · Blood Cancer Journal · 28
PDF
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin
2019 · Michael Lauseker, Katharina Bachl, et al. · American Journal of Hematology · 28
PDF
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI
2021 · Johan Richter, Anna Lübking, et al. · Leukemia · 27
PDF
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
2019 · Anna Kreutzman, Bhagwan Yadav, et al. · OncoImmunology · 26
PDF
Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
2015 · P O Pietarinen, T Pemovska, et al. · Blood Cancer Journal · 25
PDF
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
2017 · Hanna L. M. Rajala, Mohamed El Missiry, et al. · Journal of Cancer Research and Clinical Oncology · 24
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
2022 · Jani Huuhtanen, Mette Ilander, et al. · Journal of Clinical Investigation · 22
PDF
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial
2024 · Hjalmar Flygt, Stina Söderlund, et al. · Leukemia · 18
PDF
Works count: 73
Citation count: 2,964
H-index: 23
I10-index: 34
Year
Topic
Type